Company profile
Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07012395 | phase2 | recruiting | 2025-05-27 | 2027-06-01 | Spyre Therapeutics, Inc. | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
| NCT06448247 | phase1 | completed | 2024-06-06 | 2026-03-10 | Spyre Therapeutics, Inc. | A Study of SPY001-001 in Healthy Volunteers |
| NCT06622070 | phase1 | completed | 2024-11-18 | 2026-07-28 | Spyre Therapeutics, Inc. | A Study of SPY002-072 in Healthy Volunteers |
| NCT06672718 | phase1 | completed | 2024-11-26 | 2026-08-19 | Spyre Therapeutics, Inc. | A Study of SPY002-091 in Healthy Volunteers |
| NCT06873724 | phase1 | active_not_recruiting | 2025-03-10 | 2026-11-18 | Spyre Therapeutics, Inc. | A Study of SPY003-207 in Healthy Volunteers |
FDA applications (0)
No records yet.